Brought to you by

Pfizer buys Angiosyn in deal based largely on milestones
03 Dec 2015
Executive Summary
Pfizer is acquiring privately held Angiosyn (develops therapeutics that control angiogenesis) for a small up-front fee, while the majority of the payments on the deal--worth up to $527mm--are based on Angiosyn's successful development of drugs for an ophthalmic indication and a second undisclosed therapeutic area. (Strategic Transactions assumes the up-front payment to be $132mm and the rest in earn-outs.) Pfizer will also pay sales royalties.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com